Avalo Therapeutics, Inc.
AVTXHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Avalo Therapeutics, Inc. focuses on Biotechnology services and products. Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. The $838.4M market capitalization puts AVTX squarely in small-cap range for its industry. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Market Cap
$838.4M
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
-5.56
EPS (TTM)
$-5.57
EPS (Fwd)
$-2.87
ROE
-88.8%
ROA
-41.5%
Cash
$82.0M
Total Debt
$328,000
Free CF
-$23.2M
52W Change
266.7%
Annual Financials
Cash vs Debt
With $82.0M in cash and $328K in debt, AVTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$23.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -88.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.1M (2022) to $59K (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Avalo Therapeutics, Inc.'s trajectory.